Questions // answered and cited
AOD-9604 questions, answered plainly and cited.
Mechanism, efficacy, safety, status, and history — direct answers, no marketing.
What does the peptide AOD9604 do?
AOD9604 is a growth-hormone fragment engineered to act on fat cells. In obese mice, 14 days of chronic treatment reduced body weight and fat and raised beta-3 adrenergic receptor RNA in fat tissue [1]. It inhibits the fat-building enzyme acetyl-CoA carboxylase and up-regulates fat-burning receptors — but in humans it did not produce significant weight loss [5].
How does AOD-9604 work?
AOD-9604 acts at the fat-cell membrane: it releases a second messenger that inhibits acetyl-CoA carboxylase, reducing new fat synthesis [4], and in obese mice it up-regulates beta-3 adrenergic receptors that drive fat oxidation [1]. It does not bind the growth-hormone receptor, so it does not raise IGF-1 [3]. The mechanism is well-documented in animals but did not translate to human weight loss [5].
How does AOD9604 stimulate lipolysis without affecting the HGH receptor?
AOD9604 is a C-terminal fragment of growth hormone, not the whole hormone, so it lacks the part that binds the growth-hormone receptor. Instead it acts directly at the adipocyte membrane, releasing a second messenger that inhibits acetyl-CoA carboxylase [4]. Because it never engages the GH receptor, it does not raise IGF-1 [3] — the basis for its receptor-sparing design.
Does AOD9604 work by activating beta-3 adrenergic receptors?
Partly. In obese mice, chronic AOD9604 up-regulated beta-3 adrenergic receptor RNA, and the chronic weight-loss effect was abolished in beta3-AR knockout mice — while acute increases in energy expenditure and fat oxidation persisted without it [1]. So the long-term fat-reducing effect depends on beta3-AR signaling, but the immediate metabolic effect does not run solely through that receptor.
What is the mechanism of action of AOD9604?
AOD9604 inhibits acetyl-CoA carboxylase via a membrane-derived second messenger, suppressing new fatty-acid synthesis [4], and up-regulates beta-3 adrenergic receptors to promote fat oxidation in obese mice [1]. It does not engage the growth-hormone receptor and does not raise IGF-1 [3]. This mechanism is characterized chiefly in mouse, rat, and cell models — not proven in humans [5].
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide modeled on the C-terminal region of human growth hormone (residues 177–191) with an added N-terminal tyrosine [3]. It was developed as an oral anti-obesity drug to mobilize fat without raising IGF-1. It is investigational and not approved for any indication; the obesity program was discontinued after the pivotal trial failed [14].
Does AOD-9604 actually work?
For fat loss in humans, the evidence says no. Across roughly six trials totaling about 900 obese adults at daily oral doses from 0.25 mg to 54 mg, the pivotal Phase IIb trial showed no statistically significant weight loss versus placebo, and the program was discontinued [5][14]. The fat-metabolism mechanism is real in animals [1], but it did not translate into proven human weight loss.
Is AOD-9604 FDA approved?
No. AOD-9604 is not FDA-approved for any indication. The anti-obesity development program run by Metabolic Pharmaceuticals was discontinued after the pivotal Phase IIb trial failed to meet its primary endpoint [14]. It was reviewed by the FDA Pharmacy Compounding Advisory Committee in December 2024 (docket FDA-2024-N-4777) regarding 503A compounding eligibility; that status should be independently verified.
Is AOD-9604 safe?
In the trials that were run, tolerability resembled placebo: across about 900 obese adults, the safety profile was indistinguishable from placebo and free of the adverse effects tied to full growth hormone [5], and non-clinical work found no genotoxic or toxicological concerns [6]. However, there is no long-term human safety data beyond about 24 weeks, and it remains investigational [14].
Does AOD9604 raise IGF-1 like HGH?
No. AOD9604 is designed not to raise IGF-1 because it does not bind the growth-hormone receptor [3]. That is the central distinction from full human growth hormone, which raises IGF-1 and drives growth signaling. Non-clinical evaluation found it generally safe after chronic oral administration in rats and primates, consistent with the absence of growth-hormone-type effects [6].
Why was AOD-9604 discontinued as a pharmaceutical drug?
Because it did not work for its intended purpose. Across roughly six placebo-controlled trials in about 900 obese adults, the pivotal Phase IIb obesity trial did not show statistically significant weight loss versus placebo, so Metabolic Pharmaceuticals discontinued the obesity development program around 2007 [5][14]. The safety profile was fine; the efficacy endpoint was not met.
What is the half-life of AOD9604?
About 3 minutes after intravenous injection in a pig pharmacokinetic model — the intact peptide is cleared rapidly, degrading by sequential removal of amino acids from the N-terminus [6]. That very short systemic half-life is one reason the human obesity program used an oral tablet, for which absorption was demonstrated [6].
Is AOD9604 orally bioavailable or does it have to be injected?
It was developed and tested as an orally dosed agent — the entire Metabolic Pharmaceuticals human obesity program used oral tablets, and non-clinical work demonstrated oral absorption [6]. So an injection is not required for systemic exposure. Other routes (intravenous, intra-articular, intraperitoneal) were used only to answer specific research questions [1][6][7].
Does AOD9604 affect insulin or blood sugar levels?
Unlike full growth hormone, AOD9604 was designed to avoid the diabetogenic, insulin-resistance-promoting effects associated with raising IGF-1, since it does not engage the GH receptor [3]. Early work documented effects of an antilipogenic hGH fragment on glucose transport in rat adipocytes [8], and non-clinical evaluation found it generally safe after chronic dosing [6]. No human glucose-control benefit is established.
What are the side effects of AOD9604?
In human trials, the side-effect profile was indistinguishable from placebo and free of the adverse effects tied to full growth hormone [5]; non-clinical work found no genotoxic or toxicological signals [6]. The most common real-world complaint is minor injection-site redness, a generic reaction to subcutaneous injection. Long-term safety beyond about 24 weeks is uncharacterized [14].
Is AOD9604 banned in competitive sports?
Yes. As a growth-hormone fragment, AOD-9604 falls under the World Anti-Doping Agency Prohibited List, Section S2, and is prohibited at all times in sport [11]. Dedicated assays can detect it even though it does not interfere with the standard growth-hormone immunoassay [13]. Marketing claims that it is "not banned" are incorrect — athletes should treat it as a prohibited substance.
Is AOD9604 a steroid?
No. AOD9604 is a peptide — a 16-amino-acid fragment of growth hormone [3] — not an anabolic steroid. It is structurally and mechanistically unrelated to steroids, acting on fat-cell metabolism via acetyl-CoA carboxylase inhibition and beta-3 receptor up-regulation [1][4] rather than through androgen receptors.
What happened in the AOD9604 Phase IIb clinical trial?
The pivotal Phase IIb obesity trial did not produce statistically significant weight loss versus placebo. It was part of a program of roughly six placebo-controlled trials in about 900 obese adults at daily oral doses from 0.25 mg to 54 mg [5]. After the primary endpoint was missed, Metabolic Pharmaceuticals discontinued the obesity development program around 2007 [14].
How much weight can you lose on AOD9604 peptide?
The human evidence does not support meaningful weight loss. Across about 900 obese adults in roughly six trials, the pivotal Phase IIb trial showed no statistically significant weight loss versus placebo [5], and the program was discontinued [14]. The most common community report is no noticeable fat loss — consistent with those null trials. Any number promising a specific loss is not backed by the clinical record.
Does AOD9604 help with cartilage repair and osteoarthritis?
Only in preclinical models so far. In 32 rabbits with collagenase-induced knee osteoarthritis, weekly intra-articular injection of 0.25 mg AOD9604 (with or without hyaluronic acid) for 4–7 weeks reduced cartilage-degeneration scores versus saline [7]. This is a single animal model plus in-vitro work; there are no published human osteoarthritis trials of AOD-9604 itself.
Does AOD9604 preserve muscle mass while reducing fat?
There is no human evidence for this. Unlike growth hormone, users generally report no muscle, strength, or recovery changes, consistent with AOD-9604 not engaging the growth-hormone receptor [3]. The human obesity trials measured weight and safety, not body-composition partitioning, and did not show significant weight loss to begin with [5].
Where do you inject AOD-9604?
This site does not provide administration or dosing instructions, because AOD-9604 is investigational and not approved for human use. For context only: the human obesity program used an oral tablet, not injection, since oral absorption was demonstrated and the intravenous half-life is only about 3 minutes [6]. Injectable routes in the literature were experimental, for animal studies.